Compactin Suppresses Bone Resorption by Inhibiting the Fusion of Prefusion Osteoclasts and Disrupting the Actin Ring in Osteoclasts
- 1 April 2000
- journal article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 15 (4) , 650-662
- https://doi.org/10.1359/jbmr.2000.15.4.650
Abstract
Compactin (mevastatin), which inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, and thus biosynthesis of cholesterol and the prenylation of proteins, inhibits osteoclastic bone resorption. Although it has been suggested that compactin inhibits bone resorption by inducing apoptosis of osteoclasts, the pathway by which compactin inhibits resorption has not been established. We investigated the effect of compactin on the differentiation of osteoclasts and the relationship between the morphological changes elicited by compactin and its inhibitory effect on bone resorption. Compactin inhibited the differentiation of osteoclasts, interfering with the fusion process by which prefusion osteoclasts (pOCs) develop into multinucleated osteoclast-like cells (OCLs), and also disrupted the actin ring of OCLs. The potency of compactin to inhibit fusion of pOCs and to disrupt the actin ring of OCLs corresponded to that of compactin to inhibit bone resorption. The effects of compactin were prevented by the addition of MVA lactone or its downstream products farnesylpyrophosphate (FPP) and geranylgeranyl-pyrophosphate (GGPP) but not by squalene. Apoptosis of OCLs was not induced by the concentration of compactin that inhibited fusion of pOCs and disrupted the actin ring. The normal process of pOC fusion and the integrity of the actin ring were restored by the withdrawal of compactin from the cultures after they had been treated with compactin for 24 h, but they were not restored by the addition of zVAD-fmk, a caspase inhibitor. Compactin also reversibly inhibited interleukin-1beta (IL-1beta)-, 1alpha,25-dihydroxyvitamin D3 (1 alpha,25(OH)2D3)-, and parathyroid hormone (PTH)-stimulated 45Ca release in bone organ cultures. Our results indicate that the inhibitory effects of compactin on bone resorption result from the inhibition of fusion of pOCs into OCLs and disruption of actin ring in OCLs and that apoptosis of OCLs is not necessary for these inhibitory effects of compactin. These effects of compactin are likely to be a consequence of the inhibition of prenylation of proteins that play an important role in the fusion of pOCs and in maintaining actin ring integrity in OCLs.Keywords
This publication has 56 references indexed in Scilit:
- Vitamin K2Inhibits Osteoclastic Bone Resorption by Inducing Osteoclast ApoptosisBiochemical and Biophysical Research Communications, 1996
- Possible involvement of focal adhesion kinase, p125FAK, in osteoclastic bone resorptionJournal of Cellular Biochemistry, 1995
- Wortmannin, a specific inhibitor of phosphatidylinositol‐3 kinase, blocks osteoclastic bone resorptionFEBS Letters, 1995
- Inhibition of Isoprenoid Biosynthesis Induces Apoptosis in Human Promyelocytic HL-60 CellsBiochemical and Biophysical Research Communications, 1994
- Evidence That c-src Is Involved in the Process of Osteoclastic Bone ResorptionBiochemical and Biophysical Research Communications, 1994
- Inhibitory effect of ipriflavone on osteoclast-mediated bone resorption and new osteoclast formation in long-term cultures of mouse unfractionated bone cellsCalcified Tissue International, 1993
- Participation of cathepsin L on bone resorptionFEBS Letters, 1993
- Regulation of intracellular actin polymerization by prenylated cellular proteinsThe Journal of cell biology, 1992
- Inhibition of osteoclast proton transport by bafilomycin A1 abolishes bone resorptionBiochemical and Biophysical Research Communications, 1990
- Discovery, biochemistry and biology of lovastatinThe American Journal of Cardiology, 1988